Analysts at H.C. Wainwright have lowered their price target for Cocrystal Pharma (COCP, Financial), cutting it to $6 from a previous target of $7 while maintaining a Buy rating. The adjustment is attributed to expectations of equity dilution, although the firm remains optimistic about the company's prospects. Cocrystal Pharma's candidate, CDI-988, has shown promising activity against emerging norovirus strains, further supporting their positive stance on the stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Cocrystal Pharma Inc (COCP, Financial) is $8.33 with a high estimate of $10.00 and a low estimate of $7.00. The average target implies an upside of 437.63% from the current price of $1.55. More detailed estimate data can be found on the Cocrystal Pharma Inc (COCP) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Cocrystal Pharma Inc's (COCP, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
